Guggenheim Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock

Key Points

• Guggenheim raised its Neurocrine Biosciences price target from $207 to $224 and maintained a Buy rating, implying 37.67% upside from the prior close. Analysts’ consensus rating is Moderate Buy, with an average target of $202.32.
• Neurocrine reported strong quarterly results: revenue increased 41.3% year over year to $1.12 billion, and EPS of $3.29 beat the $1.91 consensus. The company also raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion.
• Shares traded at $162.71 in Wednesday’s midday session. Insider sales and reported Soleno acquisition integration risks are potential concerns, though some insider transactions were under pre-arranged trading plans.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its price target boosted by analysts at Guggenheim from $207.00 to $224.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price target would suggest a potential upside of 37.67% from the company's previous close.

A number of other research firms also recently issued reports on NBIX. Wall Street Zen downgraded shares of Neurocrine Biosciences from a "buy" rating to a "hold" rating in a research report on Sunday, August 9th. Wells Fargo & Company lifted their price target on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. Morgan Stanley lifted their price target on shares of Neurocrine Biosciences from $183.00 to $185.00 and gave the company an "equal weight" rating in a research report on Tuesday. Zacks Research downgraded shares of Neurocrine Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada increased their price objective on shares of Neurocrine Biosciences from $187.00 to $190.00 and gave the stock an "outperform" rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $202.32.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $2.14 during midday trading on Wednesday, reaching $162.71. The stock had a trading volume of 244,883 shares, compared to its average volume of 1,229,311. Neurocrine Biosciences has a twelve month low of $122.14 and a twelve month high of $186.12. The stock has a market capitalization of $16.54 billion, a PE ratio of 24.30, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. The stock's 50-day simple moving average is $146.72 and its 200 day simple moving average is $147.60.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $1.38. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a return on equity of 24.11% and a net margin of 18.98%. The firm's quarterly revenue was up 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.04 earnings per share. Equities analysts predict that Neurocrine Biosciences will post 7.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 2,311 shares of the company's stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.20, for a total value of $363,289.20. Following the transaction, the chief financial officer directly owned 42,808 shares of the company's stock, valued at $6,729,417.60. This represents a 5.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,200 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total value of $1,197,864.00. Following the transaction, the director owned 10,386 shares of the company's stock, valued at approximately $1,727,918.82. This trade represents a 40.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,137 shares of company stock worth $2,829,332 in the last three months. 4.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at $2,310,886,000. Renaissance Technologies LLC boosted its stake in shares of Neurocrine Biosciences by 8.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company's stock worth $318,665,000 after acquiring an additional 180,100 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Neurocrine Biosciences by 97.0% during the 1st quarter. First Trust Advisors LP now owns 959,217 shares of the company's stock worth $126,367,000 after acquiring an additional 472,408 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter worth $117,827,000. Finally, Ieq Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter worth $107,914,000. 92.59% of the stock is currently owned by institutional investors.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, beating estimates; earnings of $3.29 per share also topped consensus. Product sales exceeded $1 billion for the first time, and Neurocrine raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion. Q3 results and guidance
• Positive Sentiment: Several analysts raised their price targets after the results, including Canaccord to $220, Piper Sandler to $215 and RBC to $190. Their ratings were mostly positive, though Morgan Stanley maintained an equal-weight rating.
• Positive Sentiment: Neurocrine has started a Phase 2 Alzheimer’s study, adding a pipeline development to the near-term commercial growth story. Alzheimer’s study update
• Neutral Sentiment: A report flagged integration challenges and legacy liabilities as risks to Neurocrine’s ability to realize value from its Soleno acquisition. Soleno acquisition risks
• Negative Sentiment: Director George J. Morrow reported selling shares in several transactions. The sales were made under a pre-arranged Rule 10b5-1 plan, which may temper the signal, but insider selling can weigh on sentiment.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.